Literature DB >> 25618475

Neurocognitive functioning in the premorbid stage and in the first episode of bipolar disorder: a systematic review.

Diego J Martino1, Cecilia Samamé2, Agustín Ibañez3, Sergio A Strejilevich4.   

Abstract

It is well known that patients with bipolar disorder (BD) have cognitive impairments even during periods of euthymia. However, to date it remains unclear the moment when these deficits onset. Therefore, the aim of this study was to review the evidence focusing on the cognitive status of patients with BD in their premorbid stage and in their first episode. An extensive search was conducted through the online databases Pubmed/PsychInfo, covering the period between 1980 and 2014. A total of 23 studies were selected for the review (nine studies explored premorbid stage of people who lately develop BD and 14 examined first-episodes in bipolar patients). There is evidence that general intelligence is not impaired in the premorbid stage. Impairments in verbal memory, attention, and executive functions tend to be present during and after the first episode. Preliminary evidence suggests that these deficits in specific cognitive domains might precede the onset of illness.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cognition; Executive functions; High-risk; Memory

Mesh:

Year:  2015        PMID: 25618475     DOI: 10.1016/j.psychres.2014.12.044

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  15 in total

Review 1.  Cognitive Impairment in Patients with Bipolar Disorder: Impact of Pharmacological Treatment.

Authors:  Ni Xu; Benjamin Huggon; Kate E A Saunders
Journal:  CNS Drugs       Date:  2020-01       Impact factor: 5.749

Review 2.  Neurocognitive functioning in bipolar disorder: What we know and what we don't.

Authors:  Kamyar Keramatian; Ivan J Torres; Lakshmi N Yatham
Journal:  Dialogues Clin Neurosci       Date:  2022-06-01

Review 3.  Cognitive Remediation in Psychiatric Disorders: State of the Evidence, Future Perspectives, and Some Bold Ideas.

Authors:  Wolfgang Trapp; Andreas Heid; Susanne Röder; Franziska Wimmer; Göran Hajak
Journal:  Brain Sci       Date:  2022-05-24

4.  Maternal T. gondii, offspring bipolar disorder and neurocognition.

Authors:  David Freedman; Yuanyuan Bao; Ling Shen; Catherine A Schaefer; Alan S Brown
Journal:  Psychiatry Res       Date:  2016-07-07       Impact factor: 3.222

Review 5.  Cognitive Deficits in Psychotic Disorders: A Lifespan Perspective.

Authors:  Julia M Sheffield; Nicole R Karcher; Deanna M Barch
Journal:  Neuropsychol Rev       Date:  2018-10-20       Impact factor: 7.444

6.  The neurocognitive functioning in bipolar disorder: a systematic review of data.

Authors:  Eirini Tsitsipa; Konstantinos N Fountoulakis
Journal:  Ann Gen Psychiatry       Date:  2015-12-01       Impact factor: 3.455

Review 7.  Neurobiology of Risk for Bipolar Disorder.

Authors:  Ayşegül Özerdem; Deniz Ceylan; Güneş Can
Journal:  Curr Treat Options Psychiatry       Date:  2016-10-20

Review 8.  Cognitive Impairment in Bipolar Disorder: Treatment and Prevention Strategies.

Authors:  Brisa Solé; Esther Jiménez; Carla Torrent; Maria Reinares; Caterina Del Mar Bonnin; Imma Torres; Cristina Varo; Iria Grande; Elia Valls; Estela Salagre; Jose Sanchez-Moreno; Anabel Martinez-Aran; André F Carvalho; Eduard Vieta
Journal:  Int J Neuropsychopharmacol       Date:  2017-08-01       Impact factor: 5.176

Review 9.  Use of the MATRICS consensus cognitive battery (MCCB) to evaluate cognitive deficits in bipolar disorder: A systematic review and meta-analysis.

Authors:  Qijing Bo; Zhen Mao; Xianbin Li; Zhimin Wang; Chuanyue Wang; Xin Ma
Journal:  PLoS One       Date:  2017-04-24       Impact factor: 3.240

10.  Cognitive Remediation Interventions in Schizoaffective Disorder: A Systematic Review.

Authors:  Ester Lopez-Fernandez; Brisa Sole; Esther Jimenez; Estela Salagre; Anna Gimenez; Andrea Murru; Caterina Del Mar Bonnín; Benedikt Lorenz Amann; Iria Grande; Eduard Vieta; Anabel Martínez-Aran
Journal:  Front Psychiatry       Date:  2018-10-04       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.